SANGIOLO, Dario
 Distribuzione geografica
Continente #
NA - Nord America 5.243
EU - Europa 2.934
AS - Asia 1.660
SA - Sud America 45
OC - Oceania 34
AF - Africa 32
Continente sconosciuto - Info sul continente non disponibili 9
Totale 9.957
Nazione #
US - Stati Uniti d'America 4.910
CN - Cina 928
IT - Italia 851
DE - Germania 529
GB - Regno Unito 331
CA - Canada 313
IE - Irlanda 292
SE - Svezia 254
TR - Turchia 196
FR - Francia 145
VN - Vietnam 109
FI - Finlandia 102
JP - Giappone 98
UA - Ucraina 92
PL - Polonia 88
KR - Corea 86
IN - India 52
ES - Italia 45
TW - Taiwan 45
SG - Singapore 40
HK - Hong Kong 32
NL - Olanda 32
AU - Australia 29
BE - Belgio 26
TH - Thailandia 24
NO - Norvegia 23
AT - Austria 21
BR - Brasile 20
RU - Federazione Russa 20
CH - Svizzera 16
MX - Messico 16
PT - Portogallo 14
SN - Senegal 14
IR - Iran 12
RO - Romania 11
SA - Arabia Saudita 11
AR - Argentina 10
HR - Croazia 9
IL - Israele 9
EU - Europa 7
CO - Colombia 6
GR - Grecia 6
BY - Bielorussia 5
EG - Egitto 5
HU - Ungheria 5
NZ - Nuova Zelanda 5
UZ - Uzbekistan 5
VE - Venezuela 5
LT - Lituania 4
ZA - Sudafrica 4
AE - Emirati Arabi Uniti 3
BA - Bosnia-Erzegovina 3
CZ - Repubblica Ceca 3
KE - Kenya 3
MK - Macedonia 3
NG - Nigeria 3
PA - Panama 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
CL - Cile 2
DK - Danimarca 2
MA - Marocco 2
MY - Malesia 2
PK - Pakistan 2
BT - Bhutan 1
GA - Gabon 1
ID - Indonesia 1
LV - Lettonia 1
OM - Oman 1
PE - Perù 1
PH - Filippine 1
PR - Porto Rico 1
SI - Slovenia 1
UY - Uruguay 1
Totale 9.957
Città #
Chandler 523
Fairfield 406
Beijing 366
Houston 342
Munich 317
Dublin 290
Mcallen 278
Montréal 273
Ashburn 253
Torino 201
Woodbridge 198
Ann Arbor 182
Seattle 169
Wilmington 146
Jacksonville 135
Nyköping 121
Cambridge 116
Shanghai 101
Pisa 100
Turin 95
Redwood City 94
New York 92
Medford 89
Dearborn 79
Villeurbanne 78
Princeton 77
Warsaw 70
Dong Ket 55
Milan 52
Guangzhou 47
Fremont 40
Nanjing 37
Taipei 35
Boston 34
San Diego 32
Hangzhou 30
Xian 24
Wuhan 23
Washington 20
Seoul 19
Zhengzhou 17
Hebei 16
Hefei 16
Singapore 16
Tokyo 16
Boardman 15
Brussels 15
Chengdu 15
Phoenix 14
Upper Marlboro 14
Istanbul 13
Pune 13
Rome 13
Silver Spring 13
Stavanger 13
Toronto 13
Changsha 12
Dallas 12
Kunming 12
Vienna 12
Chicago 11
Dresden 11
Florence 11
Norwalk 11
San Mateo 11
Carrara 10
Changchun 10
Jinan 10
Los Angeles 10
Madrid 10
Paris 10
Bari 9
Berlin 9
Columbus 9
Detroit 9
Falls Church 9
Fuzhou 9
Mountain View 9
Ankara 8
Bangkok 8
Birmingham 8
Chongqing 8
Heidelberg 8
San Francisco 8
Buenos Aires 7
Central 7
Central District 7
Cuneo 7
Genoa 7
Izmir 7
Mumbai 7
Ottawa 7
Paredes 7
Shenzhen 7
Tappahannock 7
A Coruña 6
Billings 6
Bologna 6
Brookline 6
Cincinnati 6
Totale 6.252
Nome #
Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective. 1.371
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial 1.041
Complete Resolution of Life-Threatening Bleomycin-Induced Pneumonitis After Treatment With Imatinib Mesylate in a Patient With Hodgkin's Lymphoma: Hope for Severe Chemotherapy-Induced Toxicity? 457
Ex Vivo-Activated MHC-Unrestricted Immune Effectors for Cancer Adoptive Immunotherapy 414
Cytokine Induced Killer cells kill chemo-surviving melanoma cancer stem cells 302
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group 257
Genetically Redirected T Lymphocytes for Adoptive Immunotherapy of Solid Tumors. 231
VEGF blockade enhances the antitumor effect of BRAFV600E inhibition 203
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models 192
BRAF and MEK inhibitors increase PD1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD1 antibody 187
Adoptive immunotherapy against ovarian cancer 167
Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. 166
Post-Transplant Cyclophosphamide and Tacrolimus–Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors 160
Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. 146
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma 146
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity 145
Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives 142
CD44v6 as innovative sarcoma target for CAR-redirected CIK cells 141
Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy 133
Activity of cytokine-induced killer cells against bone and soft tissue sarcoma. 131
Pazopanib and trametinib as a synergistic strategy against osteosarcoma: Preclinical activity and molecular insights 131
Cytokine Induced Killer cells effectively kill chemo-resistant melanoma cancer stem cells. 127
Abstract LB-366: Everolimus (EV) potentiates Sorafenib (SOR)activity in osteosarcoma (OS) preclinical models: a combination targeting the crosstalk between ERK1/2 and mTORC1/2 signaling pathways 117
Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer 115
Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma 111
CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy 108
Next generation immune-checkpoints for cancer therapy 103
Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. 101
Recent advances in the development of breast cancer vaccines. 100
NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives 97
CSPG4-specific CAR.CIK lymphocytes as a novel therapy for the treatment of multiple soft tissue sarcoma histotypes 94
Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors 91
Treatment of metastatic melanoma: a multidisciplinary approach 86
Abstract 5603: Melanoma PD1 expression is upregulated by MAPK inhibitors leading to an immune-independent synergism with anti-PD1 antibodies 83
Efficient transcriptional targeting of human hematopoietic stem cells and blood cell lineages by lentiviral vectors containing the regulatory element of the Wiskott-Aldrich Syndrome gene 82
Recruitment, infiltration and cytotoxicity of hla-independent killer lymphocytes in three-dimensional melanoma models 82
Cytokine Induced Killer cells immunotherapy overcomes the resistance to MET tyrosine kinase inhibitors in nonsmall cell lung cancer 81
INCIDENCE OF HHV-6 AFTER NONMYELOABLATIVE HSCT IN REFRACTORY MALIGNANCIES 80
Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells 80
Comparison of post-transplant events and outcomes in patients affected by haematological or solid malignancies undergone to a non-myeloablative allogeneic haematopoietic stem cell transplantation in progressive disease 79
DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination 78
Gene-modified T lymphocytes in the setting of hematopoietic cell transplantation: potential benefits and possible risks. 78
Adoptive immunotherapy against sarcomas. 78
Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells 77
Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours 76
Ex Vivo Allogeneic Stimulation Significantly Improves Expansion of Cytokine-Induced Killer Cells Without Increasing Their Alloreactivity Across HLA Barriers. 75
Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation 74
Cytokine-induced killer cells as immunotherapy for solid tumors: current evidences and perspectives 70
Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD 70
Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective 69
Cytokine-induced killer cells engineered with exogenous t-cell receptors directed against melanoma antigens: Enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition 66
Cytokine-Induced Killer (CIK) Cells from Colorectal Cancer Patients after Nonmyeloablative Hematopoietic Cell Transplantation: Tumor Killing Capacity and Alloreactivity across MHC Barriers 65
Effective Activity of Cytokine Induced Killer Cells against Autologous Metastatic Melanoma including Cells with Stemness Features. 62
Alloreactivity and antitumor activity segregate within two distinct subsets of Cytokine-Induced Killer Cells: Implications for their infusion Across major HLA-barriers. 61
Cytokine profiling of end stage cancer patients treated with immunotherapy 61
TCR gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naïve and memory T-cells without prior stimulation of endogenous TCR 60
Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectors. 60
Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour 60
Veliparib: a new therapeutic option in ovarian cancer? 54
Sequential Lentiviral Transduction Conferring Simultaneous Sensitivity to Ganciclovir and Resistance to Mycophenolate Mofetil 49
Epha2 expression in bone sarcomas: Bioinformatic analyses and preclinical characterization in patient-derived models of osteosarcoma, ewing’s sarcoma and chondrosarcoma 48
Parp1 inhibitor and trabectedin combination does not increase tumor mutational burden in advanced sarcomas—a preclinical and translational study 48
Role of interferon in melanoma: old hopes and new perspectives 44
Outcome of allogeneic hematopoietic cell transplantation (HCT) for patients with severe aplastic anemkia (SAA) above the age of 40 years 43
Treating breast cancer with cell-based approaches: an overview 42
The Combination of Sorafenib and Everolimus abrogates mTORC-1 and mTORC2 up-regulation in preclinical models of Osteosarcoma. 42
Delving into PARP inhibition from bench to bedside and back 42
Oncoretroviral and Lentiviral Transduction of Donor T Cells to Facilitate Engraftment of Dog Leukocyte Antigen (DLA)-Haploidentical T-Cell-Depleted Marrow 40
Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. 37
Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age. 33
The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies 33
Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer 32
Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy 32
Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study 30
Redirecting GVT after Allografting in Colorectal Cancer: Active Vaccination and Adoptive Immunotherapy 30
Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review 30
Immunotherapy associated pulmonary toxicity: Biology behind clinical and radiological features 30
Survivin-peptide vaccination elicits immune response after allogeneic nonmyeloablative transplantation: a safe strategy to enhance the graft versus tumor effect 29
Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST 28
Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti-leukaemic potential and alloreactivity across major human leukocyte antigen barriers 25
Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19 22
Redirectedt cells in cancer therapy 21
Lentiviral vector conferring resistance to mycophenolate mofetil and sensitivity to ganciclovir for in vivo T-cell selection 19
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study 14
Dual VEGFA/BRAF targeting boosts PD-1 blockade in melanoma through GM-CSF-mediated infiltration of M1 macrophages 14
Significance of TIM3 expression in cancer: From biology to the clinic 13
PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade 12
CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma 8
Fibroblasts Impair Migration and Antitumor Activity of NK-92 Lymphocytes in a Melanoma-on-Chip Model 6
Epigenetic determinants in soft tissue sarcomas: molecular mechanisms and therapeutic targets 6
Cytokine induced killer cells as promising immunotherapy for solid tumors 5
Platinum-based chemotherapy attenuates the effector response of CD8 T cells to concomitant PD-1 blockade 3
Predictive Factors in Metastatic Melanoma Treated with Immune Checkpoint Inhibitors: From Clinical Practice to Future Perspective 1
Cytokine-induced killer (CIK) cells, successes and challenges: report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapy 1
Totale 10.286
Categoria #
all - tutte 23.419
article - articoli 0
book - libri 0
conference - conferenze 2.091
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.510


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019554 0 0 0 0 0 0 0 0 0 161 251 142
2019/20201.863 106 95 97 233 142 293 188 176 161 158 98 116
2020/20211.305 84 125 89 114 98 86 76 80 110 132 110 201
2021/20221.235 69 91 48 74 73 47 86 74 60 111 279 223
2022/20231.779 126 171 42 174 129 400 148 127 216 53 123 70
2023/2024806 109 158 74 84 62 161 56 59 11 32 0 0
Totale 10.286